Gynecological cancers are a leading cause of cancer-related deaths worldwide, with cervical and endometrial cancers being the most prevalent uterine cancers. Estimating cancer burden is vital for setting disease control priorities. Global cancer statistics show gynecological cancers accounted for 19% of new cases and 2.9 million deaths among women in 2002. Cervical cancer alone caused 493,000 new cases and 273,000 deaths, while endometrial cancer led to 199,000 new cases and 50,000 deaths. Over 80% of cervical cancer cases occur in developing countries. Investment in healthcare infrastructure and human resources is crucial to reducing this burden, especially in low-and medium-resource countries. The current treatment methods for these cancers are inadequate, resulting in adverse effects and treatment resistance. To improve treatment efficacy and patient quality of life, there is a critical need for novel adjuvant treatments. Curcumin, a natural compound, shows promise as a therapeutic agent with potent anticancer effects. Recent studies have demonstrated the anticancer effects of curcumin and its analogues against gynecological malignancies, highlighting their potential as therapeutic interventions in these diseases. Before assessing the antitumor effect, the retention properties of CU(βCD)2-Psomes were examined by incubating purified samples under different pH values in a microenvironment for 24 h (Figure ). Notably, at pH 7.5, after 24 h, only 20% is released, consistent with the observed antitumor effect (Figure ). Additionally, at pH 5, the release profile is accelerated, with 60% of CU(βCD)2 being released after 8 h (Figure ).